贝利尤单抗治疗IgA肾病的真实世界疗效与安全性
BACKGROUND: Belimumab, a monoclonal antibody targeting B lymphocyte stimulator, has shown benefits in systemic lupus erythematosus and lupus nephritis, but its role in IgA nephropathy (IgAN) remains unclear. We evaluated the effectiveness and safety of belimumab in IgAN.…
要点
- 新诊断患者中贝利尤单抗组3个月和6个月缓解率均显著更高。
- 贝利尤单抗组常见不良事件发生率未增加。
核心结论
- 贝利尤单抗治疗与IgA肾病患者更高的蛋白尿缓解率相关,且未增加常见不良事件发生率。
研究设计与样本
- 回顾性队列研究,纳入中国同济医院2020年7月至2024年6月经活检证实的IgA肾病患者。
主要发现
- 总体206例患者中173例(84%)在12个月内达到蛋白尿缓解。
- 基线UPCR>600 mg/g及接受RAAS抑制剂的患者中,贝利尤单抗显示相当或更优的蛋白尿降低。
关键数值与推荐
- 蛋白尿缓解定义为24小时尿蛋白排泄量或UPCR降至基线值的50%以下。
- 贝利尤单抗组常见不良事件未超过对照组。
临床怎么用
- 在真实世界临床实践中,贝利尤单抗可能作为IgA肾病的一种更优治疗选择,尤其对新诊断患者。
- 对于基线UPCR>600 mg/g或正在使用RAAS抑制剂的患者,贝利尤单抗仍显示可比或更优的蛋白尿降低效果。
局限性
- 本研究为单中心回顾性队列研究,可能存在选择偏倚和残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Belimumab, a monoclonal antibody targeting B lymphocyte stimulator, has shown benefits in systemic lupus erythematosus and lupus nephritis, but its role in IgA nephropathy (IgAN) remains unclear. We evaluated the effectiveness and safety of belimumab in IgAN. METHODS: This retrospective cohort study included biopsy-proven IgAN patients at Tongji Hospital, China (July 2020-June 2024). Sixty-nine patients treated with belimumab were compared with 137 propensity score-matched controls receiving standard therapy. The primary outcome was proteinuria remission, defined as a reduction in 24-h urinary protein excretion or urinary protein-to-creatinine ratio (UPCR) to <50% of baseline. RESULTS: Among 206 patients with IgAN (median age 37 years, baseline estimated glomerular filtration rate 79 ml/min/1.73 m², proteinuria 1.1 g/24 h), 173 (84%) achieved proteinuria remission within 12 months. Remission was higher in the belimumab group: 59% vs 46% at 3 months, 77% vs 66% at 6 months, and 93% vs 80% at 12 months (P = .025 at 12 months), with lower time-averaged UPCR at 6 months [371 (248 738) vs 463(262 855) mg/g] and 12 months [360 (234 560) vs 433(243 720) mg/g, P = .066]. In newly diagnosed patients, remission was significantly higher at 3 months (76.5% vs 47.1%, P = .009) and 6 months (88.2% vs 67.6%, P = .045), with similar trends at later time points. In patients with baseline UPCR >600 mg/g and those receiving RAAS inhibitors, belimumab demonstrated comparable or superior proteinuria reduction. No excess of common adverse events was observed in the belimumab group. CONCLUSION: Belimumab treatment was associated with higher proteinuria remission rates in patients with IgAN, without an increased incidence of common adverse events. These findings suggest that belimumab may represent a superior therapeutic approach for IgAN in real-world clinical practice.
引用
- Wu M, Cheng Y, Zhao X, et al. Efficacy and safety of belimumab in IgA nephropathy: real-world evidence. Nephrol Dial Transplant. 2026. PMID: 41871364. doi:10.1093/ndt/gfag067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。